Mechanistic investigation and the optimal dose based on baicalin in the treatment of ulcerative colitis-A preclinical systematic review and meta-analysis

被引:0
作者
Chong, Jinchen [1 ,5 ]
Chen, Zepeng [3 ]
Ma, Jiaze [1 ,5 ]
He, Linhai [1 ,5 ]
Zhu, Yijia [1 ,5 ]
Lu, Zhihua [1 ,5 ]
Qiu, Zhengxi [1 ,5 ]
Chen, Chen [1 ]
Chen, Yugen [2 ,4 ,6 ]
Jiang, Feng [1 ,2 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Peoples R China
[2] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Colorectal Surg, Affiliated Hosp, Nanjing 210029, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China
[4] Nanjing Univ Chinese Med, Jiangsu Prov Key Lab Tumor Syst Biol & Chinese Med, Affiliated Hosp, Nanjing 210029, Peoples R China
[5] Nanjing Univ Chinese Med, Clin Med Coll, Nanjing 210023, Peoples R China
[6] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Prevent, Affiliated Hosp, Nanjing 210029, Peoples R China
基金
中国国家自然科学基金;
关键词
Baicalin; Ulcerative colitis; Animal model; Meta-analysis; Systematic review; INFLAMMATORY-BOWEL-DISEASE; THERAPEUTIC TARGETS; APOPTOSIS; STRESS; RATS; INTERLEUKIN-6; EXPRESSION; CYTOKINE; DELIVERY; PATHWAY;
D O I
10.1186/s12876-025-03629-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundUlcerative colitis (UC) is a type of inflammatory bowel disease, and current treatments often fall short, necessitating new therapeutic options. Baicalin shows therapeutic promise in UC animal models, but a systematic review is needed.MethodsA systematic search was conducted across databases including PubMed, EBSCO, Web of Science, and Science Direct, up to March 2024, identifying randomized controlled trials (RCTs) examining baicalin's impact on UC in animal models. Seventeen studies were selected through manual screening. Meta-analyses and subgroup analyses utilized Rev Man 5.3 and Stata 15.0 software to assess symptom improvement.ResultsFrom 1304 citations, 17 were analyzed. Baicalin significantly modulated various biomarkers: HCS (SMD = -3.91), DAI (MD = -2.75), spleen index (MD = -12.76), MDA (SMD = -3.88), IL-6 (SMD = -10.59), IL-1 beta (SMD = -3.98), TNF-alpha (SMD = -8.05), NF-kappa B (SMD = -5.46), TLR4 (MD = -0.38), ROR gamma (MD = -0.89), MCP-1 (MD = -153.25), MPO (SMD = -7.34), Caspase-9 (MD = -0.93), Caspase-3 (MD = -0.45), FasL (MD = -1.20)) and enhanced BWC (MD = 0.06), CL (MD = 1.39), ZO-1 (MD = 0.44), SOD (SMD = 3.04), IL-10 mRNA (MD = 3.14), and FOXP3 (MD = 0.45) levels. Baicalin's actions may involve the PI3K/AKT, TLR4/NF-kappa B, IKK/IKB, Bcl-2/Bax, Th17/Treg, and TLRs/MyD88 pathways. Optimal therapeutic outcomes were predicted at dosages of 60-150 mg/kg over 10-14 weeks.ConclusionBaicalin demonstrates a multifaceted therapeutic potential in UC, attributed to its anti-inflammatory, antioxidant, anti-apoptotic, and intestinal barrier repair properties. While higher doses and longer treatments appear beneficial, further research, particularly human clinical trials, is necessary to verify its effectiveness and safety in people.
引用
收藏
页数:21
相关论文
共 88 条
  • [21] Baicalin prevents LPS-induced activation of TLR4/NF-κB p65 pathway and inflammation in mice via inhibiting the expression of CD14
    Fu, Ya-jun
    Xu, Bo
    Huang, Shao-wei
    Luo, Xia
    Deng, Xiang-liang
    Luo, Shuang
    Liu, Chang
    Wang, Qing
    Chen, Jin-yan
    Zhou, Lian
    [J]. ACTA PHARMACOLOGICA SINICA, 2021, 42 (01) : 88 - 96
  • [22] Fuss IJ, 1996, J IMMUNOL, V157, P1261
  • [23] Antioxidant status and mineral contents in tissues of rutin and baicalin fed rats
    Gao, ZH
    Xu, HB
    Chen, XJ
    Chen, H
    [J]. LIFE SCIENCES, 2003, 73 (12) : 1599 - 1607
  • [24] Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care
    Gilliland, Ashley
    Chan, Jocelyn J.
    De Wolfe, Travis J.
    Yang, Hyungjun
    Vallance, Bruce A.
    [J]. GASTROENTEROLOGY, 2024, 166 (01) : 44 - 58
  • [25] Elevated cell-associated levels of interleukin 1 beta and interleukin 6 in inflamed mucosa of inflammatory bowel disease
    GrottrupWolfers, E
    Moeller, J
    Karbach, U
    MullerLissner, S
    Endres, S
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1996, 26 (02) : 115 - 122
  • [26] Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
    Hang, Yuanxing
    Qin, Xian
    Ren, Tianli
    Cao, Jianing
    [J]. LIPIDS IN HEALTH AND DISEASE, 2018, 17
  • [27] Paris polyphylla extract attenuates colitis in mice by regulating PPAR-γ mediated Treg/Th17 balance
    He, Long
    Yan, Xingrui
    Wen, Shuting
    Zhong, Zhuotai
    Hou, Zhengkun
    Liu, Fengbin
    Mi, Hong
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2023, 314
  • [28] Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution
    Heller, F
    Florian, P
    Bojarski, C
    Richter, J
    Christ, M
    Hillenbrand, B
    Mankertz, J
    Gitter, AH
    Bürgel, N
    Fromm, M
    Zeitz, M
    Fuss, I
    Strober, W
    Schulzke, JD
    [J]. GASTROENTEROLOGY, 2005, 129 (02) : 550 - 564
  • [29] SYRCLE's risk of bias tool for animal studies
    Hooijmans, Carlijn R.
    Rovers, Maroeska M.
    de Vries, Rob B. M.
    Leenaars, Marlies
    Ritskes-Hoitinga, Merel
    Langendam, Miranda W.
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2014, 14
  • [30] Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects
    Hu, Qichao
    Zhang, Wenwen
    Wu, Zhao
    Tian, Xin
    Xiang, Junbao
    Li, Longxuan
    Li, Zhihao
    Peng, Xi
    Wei, Shizhang
    Ma, Xiao
    Zhao, Yanling
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 165